Recent 8-K filings for NVCT

• February 11, 2026, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Nuvectis Pharma reports FY2025 net loss $26.4M; cash $31.6M; NXP900 program advancing

  Net loss $26.4M for FY2025 vs $19.0M in FY2024; includes $6.0M stock-based comp and $2.4M milestone license fees.

• August 5, 2025, 7:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01

  Nuvectis reports Q2 net loss of $6.3M; NXP900 Phase 1a complete; cash ~$39M proforma

  Net loss of $6.3M for Q2 2025 vs $4.4M for Q2 2024; increase driven by NXP900 DDI study and stock-based compensation.

• May 9, 2025, 7:59 PM ET other material materiality 0.65 neutral item 8.01item 9.01

  Nuvectis Pharma establishes $60M ATM with Leerink Partners; terminates prior HC Wainwright program

  New ATM agreement with Leerink Partners to sell up to $60M of common stock; 3.0% commission on gross proceeds.

• May 6, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Nuvectis Pharma Q1 2025 net loss $5.3M; cash $29.9M; NXP900 Phase 1b advancing

  Cash and equivalents $29.9M as of Mar 31, 2025, up from $18.5M at Dec 31, 2024, driven by $14.0M net public offering proceeds.

• February 25, 2025, 6:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Nuvectis Pharma reports FY2024 net loss of $19.0M; follow-on offering extends cash runway into 2027

  Cash and cash equivalents $18.5M as of Dec 31, 2024, down from $19.1M; net loss $19.0M, vs $22.3M in 2023.

• February 6, 2025, 6:59 PM ET other material materiality 0.65 neutral item 1.01item 8.01item 9.01

  Nuvectis Pharma prices $13.5M public offering at $5/share; full over-allotment exercised

  Priced 2.7M shares at $5.00 for $13.5M gross; underwriter fully exercised over-allotment of 405k shares, total gross $15.5M, net ~$14.4M.

• November 5, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Nuvectis Pharma Q3 2024 net loss $4.2M; NXP800 data update expected November

  Net loss $4.2M in Q3 2024 vs $5.9M Q3 2023; R&D expenses $2.8M vs $4.5M.

• August 29, 2024, 7:59 PM ET regulatory materiality 0.80 positive item 8.01item 9.01

  Nuvectis Pharma gets FDA Orphan Drug Designation for NXP800 in ARID1a-deficient ovarian cancers

  FDA granted Orphan Drug Designation for NXP800 for treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.

• May 7, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01 ◈ Earnings Releases

  Nuvectis Q1 2024 net loss $4.2M; cash $19.5M; NXP800 Phase 1b data encouraging

  Net loss $4.2M in Q1 2024 vs $4.0M in Q1 2023; cash $19.5M (up from $19.1M in Dec 2023).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.60 · Most common event earnings

5 positive 0 negative 11 neutral

source · NVCT on sec.gov